A Phase 3 interventional study of lisinopril and carvedilol controlled release formulation in Hypertension, sponsored by GlaxoSmithKline. Completed at 151 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-26.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing lisinopril in Hypertension — none open to participants now, none under way, none of them phase 3. Lisinopril · Hypertension.
Among the 30 studies testing lisinopril in Hypertension, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 3, and was the 7th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 30 studies testing lisinopril in Hypertension is open now. The open studies under Hypertension, anywhere →
Lisinopril: first FDA approval 1987 (PRINIVIL). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 654 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 55 across the 30 interventional studies. Of the 28 that completed or were terminated, 12 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 30 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
29 studies in Hypertension by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 29 finished, 7 (24%) have results posted.
Among the 29 studies in Hypertension by GlaxoSmithKline, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2006, is one of 6 in phase 3, and was the 6th registered.
GlaxoSmithKline’s Hypertension studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing lisinopril in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 29 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, double-dummy, parallel group trial employing 15 cells of a 4x4 factorial design (no placebo)to compare the hypertensive effects in patients with Stage 1 and Stage 2 hypertension of carvedilol (20, 40 or 80 mg daily) alone, lisinopril (10, 20 or 40 mg daily) alone, and all combinations of the doses.
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (ZESTRIL) or a Combination of One of the Doses of Each Medication
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented history of hypertension and receiving two antihypertensive medications with mean sDBP \<90 mmHg or for diabetic subjects (defined as having an established diagnosis of diabetes or receiving treatment for diabetes), mean sDBP \<80 mmHg. Subjects taking beta blockers, clonidine, or other antihypertensive medications where abrupt discontinuation would be of clinical concern must be tapered off the medication during the /Placebo Run-in phase to avoid rebound hypertension. All subjects must be able to be safely withdrawn from all antihypertensive treatment during the Washout/Placebo Run-in phase. Subjects should not be enrolled if the investigator thinks it is likely the subject's mean sDBP will exceed 109 mmHg or their mean sSBP will exceed 180 mmHg during the Washout/Placebo Run-in phase (NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications [e.g., Hyzaar is losartan potassium AND hydrochlorothiazide, therefore, counts as two antihypertensive medications].) OR Receiving one antihypertensive medication with mean sDBP =109 mmHg and can be safely withdrawn from all antihypertensive medication during the Washout/Placebo Run-in phase. Any subject who is receiving beta-blockers, clonidine, or other antihypertensive medications where abrupt discontinuation would be of clinical concern must have the dose tapered down during the Washout/Placebo Run-in phase to avoid rebound hypertension. All subjects must be able to be safely withdrawn from all antihypertensive treatment during the Washout/Placebo Run-in phase. Subjects should not be enrolled if the investigator thinks it is likely the subject's mean sDBP will exceed 109 mmHg or their mean sSBP will exceed 180 mmHg during the Washout/Placebo Run-in phase.
(NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications [e.g., Hyzaar is losartan potassium AND hydrochlorothiazide, therefore, counts as two antihypertensive medications].
OR Untreated/newly diagnosed subjects: mean sDBP =95 and =109, or for diabetic subjects, mean sDBP =85 and =109 (see Section 15.1, Appendix 1). If newly diagnosed, must have qualifying blood pressure confirmed on two consecutive visits with the mean sDBP value not differing more than 8 mmHg. (Previously untreated subjects include subjects who have not been treated for hypertension in the last two months.).
DAY BEFORE RANDOMIZATION: Prior to having the baseline ABPM equipment placed, subject has mean sitting cuff DBP that is ≥93 and ≤111 mmHg (or for diabetic subjects, ≥83 and ≤111 mmHg). Subjects who were taking antihypertensive medication at Screening and do not meet this criterion after one week (or 5 half-lives, whichever is longer), can return in one week ±1day and have his/her blood pressure evaluated again for this inclusion criterion.
AND
RANDOMIZATON DAY: After completion of the ABPM assessment, subject meets the following ABPM (both 12 hr and 24 hr) criteria (see Section 15.1, Appendix 1):
Exclusion Criteria:
uncontrollable or symptomatic arrhythmias unstable angina or angina treated with a beta-blocker sick sinus syndrome or second or third degree heart block (unless treated with a permanent, functioning pacemaker) bradycardia (sitting heart rate \<55 bpm) history of myocardial infarction stroke within 3 months of Screening
renal disease defined as estimated (eGFR) \<30mL/min per 1.73 m2 hepatic disease (i.e., or AST levels greater than three times the , history of hepatic impairment, or by clinical assessment) chronic biliary disorders gastric bypass surgery
any antihypertensive medication except for assigned study medication. This would include alpha blockers or other medications that may be used to treat hypertension and other conditions unrelated to hypertension; monoamine oxidase (MAO) inhibitors; any Class I or III antiarrhythmic; beta-2-agonists.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lisinopril
Drug: lisinopril
carvedilol controlled release formulation
Drug: carvedilol controlled release formulation
Also known as: lisinopril
Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure
Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP).
Time frame: Baseline, Week 6.
Change From Baseline to Week 6 in Trough Diastolic Blood Pressure
Trough ABPM was the average across 20-24 hr after dosing for each subject.
Time frame: Baseline, Week 6
Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure
Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP).
Time frame: Baseline, Week 6
Change From Baseline to Week 6 in Trough Systolic Blood Pressure
Trough ABPM was the average across 20-24 hr after dosing for each subject.
Time frame: Baseline, Week 6
Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)
Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP.
Time frame: Baseline, Week 6
Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)
Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak \> 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100.
Time frame: Baseline, Week 6
Overall Description of Safety in Each Treatment Group Using Adverse Events, Laboratory Evaluations, ECG Changes, Vital Sign Changes, and Withdrawal Rates.
Refer to Adverse Event section for safety information.
Time frame: Weeks 1 through 48
Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM
Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon.
Time frame: Morning BP, Baseline, Week 6
Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM
Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm.
Time frame: Afternoon BP, Baseline, Week 6
Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM
Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day.
Time frame: Night BP, Baseline, Week 6
Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment
Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration
Time frame: Baseline, Week 6
Diastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)
Time frame: Week 6
| Milestone | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 44 | 43 | 43 | 43 | 44 | 44 | 44 | 43 | 44 | 44 | 44 | 43 | 44 | 44 | 43 |
| Completed | 39 | 35 | 37 | 30 | 39 | 36 | 37 | 40 | 38 | 35 | 39 | 37 | 34 | 36 | 39 |
| Not completed | 5 | 8 | 6 | 13 | 5 | 8 | 7 | 3 | 6 | 9 | 5 | 6 | 10 | 8 | 4 |
| Withdrew: Adverse event | 1 | 2 | 0 | 4 | 1 | 2 | 2 | 0 | 2 | 3 | 3 | 1 | 3 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 3 | 1 | 2 | 1 | 2 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 4 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 3 | 4 | 2 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 | 3 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not listed/blank | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Per sponsors instruction | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: P.i. recommended due to blood pressure | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject did not meet end of study abpm | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Abnormal lab values | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pi recommended early withdrawal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet criteria before abpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized in error | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Failed inclusion criteria #4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Prolonged duration between visits | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Subject left town, ran out of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject refuse to sign updated consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Visits conflicted with new job | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP).
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure | -5.79 ± 5.922 | -8.11 ± 8.811 | -7.37 ± 5.914 | -4.40 ± 5.182 | -7.61 ± 4.880 | -6.52 ± 6.408 | -9.29 ± 7.226 | -8.57 ± 6.585 | -10.19 ± 6.899 | -9.36 ± 7.426 | -10.96 ± 8.388 | -10.37 ± 7.234 | -10.93 ± 5.517 | -11.09 ± 8.719 | -11.92 ± 6.887 |
Trough ABPM was the average across 20-24 hr after dosing for each subject.
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in Trough Diastolic Blood Pressure | -6.40 ± 7.982 | -6.08 ± 8.735 | -8.16 ± 7.299 | -2.34 ± 7.060 | -7.76 ± 8.285 | -5.26 ± 9.530 | -5.14 ± 7.002 | -6.36 ± 9.080 | -7.22 ± 11.284 | -6.79 ± 9.210 | -7.76 ± 11.202 | -4.90 ± 8.508 | -6.54 ± 8.305 | -7.26 ± 9.345 | -8.42 ± 7.903 |
Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP).
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure | -9.19 ± 9.415 | -13.58 ± 16.429 | -10.60 ± 8.842 | -6.15 ± 6.887 | -9.84 ± 8.471 | -10.38 ± 8.204 | -12.06 ± 11.058 | -11.58 ± 11.112 | -14.16 ± 10.783 | -11.68 ± 10.218 | -14.03 ± 11.954 | -13.90 ± 10.237 | -15.60 ± 9.777 | -15.93 ± 12.501 | -15.59 ± 11.055 |
Trough ABPM was the average across 20-24 hr after dosing for each subject.
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in Trough Systolic Blood Pressure | -9.47 ± 13.301 | -7.52 ± 12.221 | -9.54 ± 9.968 | -0.96 ± 11.447 | -9.27 ± 12.362 | -5.68 ± 14.539 | -6.44 ± 9.739 | -9.27 ± 13.582 | -9.88 ± 14.356 | -8.87 ± 11.954 | -8.11 ± 13.732 | -5.82 ± 13.878 | -9.80 ± 11.196 | -10.74 ± 12.813 | -10.00 ± 12.091 |
Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP.
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring) | -5.77 ± 0.821 | -7.55 ± 0.717 | -7.49 ± 0.877 | -5.11 ± 0.821 | -6.61 ± 0.718 | -7.13 ± 0.925 | -8.08 ± 0.472 | -9.83 ± 0.536 | -9.71 ± 0.657 | -9.55 ± 0.534 | -11.3 ± 0.645 | -11.1 ± 0.702 | -10.0 ± 0.696 | -11.7 ± 0.722 | -11.4 ± 1.042 |
Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak \> 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100.
| trough:peak ratio x 100% | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring) | 133.33 | 61.04 | 114.45 | 34.11 | 71.00 | 49.67 | 44.50 | 49.46 | 59.47 | 54.71 | 52.86 | 37.93 | 41.95 | 53.54 | 52.07 |
Refer to Adverse Event section for safety information.
Results for this outcome have not been posted.
Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon.
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in Morning SBP from Baseline to Week 6 | -9.37 ± 9.564 | -14.53 ± 17.166 | -10.76 ± 9.112 | -6.23 ± 9.159 | -10.42 ± 8.815 | -13.70 ± 10.056 | -13.89 ± 12.288 | -10.22 ± 12.734 | -14.50 ± 12.031 | -12.78 ± 14.700 | -14.29 ± 14.136 | -14.84 ± 13.383 | -17.09 ± 13.194 | -14.52 ± 15.111 | -17.12 ± 14.016 |
| Change in Morning DBP from Baseline to Week 6 | -6.12 ± 8.457 | -9.20 ± 10.516 | -7.62 ± 8.033 | -5.01 ± 7.141 | -6.82 ± 6.279 | -7.53 ± 8.206 | -9.21 ± 9.474 | -7.86 ± 8.416 | -10.04 ± 8.489 | -8.79 ± 10.902 | -11.15 ± 10.411 | -9.96 ± 10.730 | -11.95 ± 8.060 | -10.71 ± 11.012 | -12.46 ± 8.763 |
Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm.
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in Afternoon SBP from Baseline to Week 6 | -9.68 ± 11.399 | -17.21 ± 19.772 | -10.53 ± 13.359 | -9.69 ± 10.094 | -13.34 ± 9.669 | -13.76 ± 11.796 | -13.96 ± 13.128 | -15.54 ± 13.503 | -16.38 ± 13.285 | -14.51 ± 13.433 | -17.97 ± 14.622 | -17.82 ± 13.042 | -20.91 ± 13.704 | -20.46 ± 17.611 | -19.36 ± 14.893 |
| Change in Afternoon DBP from Baseline to Week 6 | -5.62 ± 7.969 | -10.25 ± 12.250 | -6.67 ± 7.800 | -6.27 ± 8.910 | -10.12 ± 6.555 | -8.38 ± 7.787 | -11.28 ± 8.998 | -12.04 ± 8.132 | -11.59 ± 10.112 | -12.18 ± 9.905 | -14.03 ± 9.425 | -12.54 ± 8.893 | -15.12 ± 8.437 | -13.87 ± 12.997 | -15.02 ± 9.197 |
Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day.
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in Night SBP from Baseline to Week 6 | -9.01 ± 10.635 | -11.58 ± 16.103 | -10.38 ± 8.600 | -4.28 ± 8.018 | -7.70 ± 10.178 | -7.71 ± 9.627 | -10.37 ± 11.517 | -9.94 ± 11.220 | -12.64 ± 11.301 | -10.02 ± 10.256 | -11.87 ± 12.031 | -11.25 ± 11.462 | -12.08 ± 9.486 | -14.12 ± 12.151 | -13.06 ± 10.651 |
| Change in Night DBP from Baseline to Week 6 | -5.83 ± 6.602 | -6.78 ± 8.251 | -7.49 ± 6.085 | -3.20 ± 5.340 | -6.49 ± 5.723 | -5.34 ± 7.187 | -8.11 ± 7.260 | -7.03 ± 6.853 | -9.36 ± 7.068 | -8.23 ± 7.458 | -9.34 ± 8.960 | -9.09 ± 7.321 | -8.27 ± 6.002 | -9.88 ± 8.161 | -10.14 ± 7.468 |
Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration
| mmHg | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in sSBP by Cuff from Baseline to Week 6 | -11.97 ± 13.671 | -10.85 ± 12.975 | -13.09 ± 10.200 | -5.68 ± 10.074 | -5.07 ± 15.610 | -8.88 ± 15.179 | -9.54 ± 14.373 | -11.84 ± 16.943 | -13.43 ± 15.279 | -9.79 ± 14.481 | -11.26 ± 15.056 | -13.49 ± 17.626 | -6.42 ± 16.409 | -9.00 ± 14.541 | -14.58 ± 16.176 |
| Change in sDBP by Cuff from Baseline to Week 6 | -7.45 ± 13.671 | -5.32 ± 8.969 | -10.35 ± 7.627 | -6.87 ± 5.671 | -5.70 ± 9.760 | -7.54 ± 8.469 | -5.66 ± 8.949 | -10.02 ± 10.384 | -10.28 ± 8.543 | -8.73 ± 10.771 | -10.89 ± 10.757 | -9.63 ± 11.073 | -8.22 ± 9.203 | -9.45 ± 11.204 | -10.95 ± 8.624 |
| participants | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diastolic Responders, Defined as ≥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of <90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures) | 22 | 23 | 27 | 20 | 18 | 17 | 20 | 28 | 25 | 30 | 22 | 27 | 28 | 24 | 28 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisinopril 10 | — | — | — |
| Lisinopril 20 | — | — | — |
| Lisinopril 40 | — | — | — |
| Carvedilol Controlled Release 20 | — | — | — |
| Carvedilol Controlled Release 40 | — | — | — |
| Carvedilol Controlled Release 80 | — | — | — |
| Carvedilol Controlled Release 20 Lisinopril 10 | — | — | — |
| Carvedilol Controlled Release 20 Lisinopril 20 | — | — | — |
| Carvedilol Controlled Release 20 Lisinopril 40 | — | — | — |
| Carvedilol Controlled Release 40 Lisinopril 10 | — | — | — |
| Carvedilol Controlled Release 40 Lisinopril 20 | — | — | — |
| Carvedilol Controlled Release 40 Lisinopril 40 | — | — | — |
| Carvedilol Controlled Release 80 Lisinopril 10 | — | — | — |
| Carvedilol Controlled Release 80 Lisinopril 20 | — | — | — |
| Carvedilol Controlled Release 80 Lisinopril 40 | — | — | — |
| Event | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/44 | 1/42 | 0/43 | 0/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| Hypertension (worsening)Vascular disorders | 0/44 | 0/42 | 0/43 | 0/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 1/42 |
| LethargyNervous system disorders | 0/44 | 1/42 | 0/43 | 0/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| ListlessPsychiatric disorders | 0/44 | 1/42 | 0/43 | 0/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| NauseaGastrointestinal disorders | 0/44 | 1/42 | 0/43 | 0/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| AlcoholismPsychiatric disorders | 0/44 | 0/42 | 0/43 | 1/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| DepressionPsychiatric disorders | 0/44 | 0/42 | 0/43 | 1/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| Drug abusePsychiatric disorders | 0/44 | 0/42 | 0/43 | 1/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| HeadacheNervous system disorders | 0/44 | 0/42 | 0/43 | 1/43 | 0/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| Ischaemic cerebral infarctionNervous system disorders | 0/44 | 0/42 | 0/43 | 0/43 | 0/43 | 0/44 | 0/44 | 1/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| Event | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/44 | 1/42 | 7/43 | 7/43 | 5/43 | 4/44 | 4/44 | 4/43 | 5/44 | 3/44 | 3/44 | 1/42 | 2/44 | 7/44 | 2/42 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/44 | 3/42 | 1/43 | 1/43 | 0/43 | 0/44 | 2/44 | 2/43 | 4/44 | 2/44 | 7/44 | 5/42 | 1/44 | 2/44 | 2/42 |
| FatigueGeneral disorders | 1/44 | 3/42 | 1/43 | 1/43 | 3/43 | 2/44 | 1/44 | 2/43 | 1/44 | 3/44 | 4/44 | 3/42 | 2/44 | 7/44 | 2/42 |
| DizzinessNervous system disorders | 3/44 | 3/42 | 3/43 | 3/43 | 4/43 | 3/44 | 1/44 | 3/43 | 6/44 | 3/44 | 5/44 | 3/42 | 2/44 | 4/44 | 0/42 |
| Upper respiratory tract infectionInfections and infestations | 3/44 | 0/42 | 2/43 | 0/43 | 0/43 | 0/44 | 3/44 | 1/43 | 5/44 | 1/44 | 1/44 | 1/42 | 1/44 | 0/44 | 1/42 |
| SinusitisInfections and infestations | 0/44 | 0/42 | 0/43 | 1/43 | 1/43 | 0/44 | 0/44 | 0/43 | 0/44 | 0/44 | 0/44 | 0/42 | 0/44 | 5/44 | 0/42 |
| DiarrhoeaGastrointestinal disorders | 1/44 | 2/42 | 0/43 | 1/43 | 0/43 | 0/44 | 1/44 | 1/43 | 2/44 | 3/44 | 2/44 | 2/42 | 1/44 | 4/44 | 1/42 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/44 | 0/42 | 2/43 | 0/43 | 0/43 | 0/44 | 0/44 | 0/43 | 4/44 | 0/44 | 0/44 | 0/42 | 0/44 | 0/44 | 0/42 |
| NasopharyngitisInfections and infestations | 0/44 | 1/42 | 1/43 | 1/43 | 0/43 | 1/44 | 1/44 | 0/43 | 1/44 | 1/44 | 3/44 | 1/42 | 0/44 | 1/44 | 3/42 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/44 | 0/42 | 1/43 | 0/43 | 1/43 | 1/44 | 0/44 | 0/43 | 0/44 | 0/44 | 1/44 | 1/42 | 0/44 | 0/44 | 3/42 |
| Age, Continuous(years) | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.3 ± 10.53 | 53.3 ± 10.69 | 51.1 ± 10.70 | 53.2 ± 9.41 | 54.1 ± 10.94 | 54.3 ± 8.64 | 53.3 ± 9.60 | 55.5 ± 8.39 | 53.5 ± 10.51 | 51.9 ± 9.08 | 51.5 ± 9.32 | 57.9 ± 9.27 | 52.5 ± 11.11 | 50.9 ± 9.51 | 51.5 ± 8.69 | 53.1 ± 9.86 |
| Gender(Participants) | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 17 | 15 | 20 | 12 | 19 | 13 | 18 | 14 | 13 | 13 | 18 | 15 | 14 | 14 | 232 |
| Male | 27 | 26 | 28 | 23 | 32 | 25 | 31 | 25 | 30 | 31 | 31 | 25 | 29 | 30 | 29 | 422 |
| Race/Ethnicity, Customized(participants) | Lisinopril 10 | Lisinopril 20 | Lisinopril 40 | Carvedilol Controlled Release 20 | Carvedilol Controlled Release 40 | Carvedilol Controlled Release 80 | Carvedilol Controlled Release 20 Lisinopril 10 | Carvedilol Controlled Release 20 Lisinopril 20 | Carvedilol Controlled Release 20 Lisinopril 40 | Carvedilol Controlled Release 40 Lisinopril 10 | Carvedilol Controlled Release 40 Lisinopril 20 | Carvedilol Controlled Release 40 Lisinopril 40 | Carvedilol Controlled Release 80 Lisinopril 10 | Carvedilol Controlled Release 80 Lisinopril 20 | Carvedilol Controlled Release 80 Lisinopril 40 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| African American/African Heritage | 10 | 14 | 9 | 16 | 11 | 13 | 12 | 11 | 12 | 18 | 14 | 13 | 16 | 14 | 11 | 194 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Asian | 3 | 1 | 3 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 3 | 3 | 4 | 33 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 29 | 28 | 31 | 26 | 30 | 29 | 30 | 30 | 29 | 23 | 27 | 27 | 25 | 26 | 27 | 417 |
| Race not provided by patient | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 7 |
Showing the first 100 of 151 sites. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jul 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisinopril